LU92389I2 - Cystéamine - Google Patents

Cystéamine Download PDF

Info

Publication number
LU92389I2
LU92389I2 LU92389C LU92389C LU92389I2 LU 92389 I2 LU92389 I2 LU 92389I2 LU 92389 C LU92389 C LU 92389C LU 92389 C LU92389 C LU 92389C LU 92389 I2 LU92389 I2 LU 92389I2
Authority
LU
Luxembourg
Prior art keywords
cysteamine
Prior art date
Application number
LU92389C
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38327943&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92389(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of LU92389I2 publication Critical patent/LU92389I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LU92389C 2006-01-27 2014-03-05 Cystéamine LU92389I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76271506P 2006-01-27 2006-01-27
PCT/US2007/002325 WO2007089670A2 (fr) 2006-01-27 2007-01-26 Cystéamine à enrobage entérique, cystamine et leurs dérivés

Publications (1)

Publication Number Publication Date
LU92389I2 true LU92389I2 (fr) 2015-10-29

Family

ID=38327943

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92389C LU92389I2 (fr) 2006-01-27 2014-03-05 Cystéamine

Country Status (20)

Country Link
US (15) US8026284B2 (fr)
EP (3) EP1919458B3 (fr)
AU (1) AU2007210005C1 (fr)
BR (1) BRPI0707277B1 (fr)
CA (1) CA2640531C (fr)
CY (1) CY1122943T1 (fr)
DK (2) DK1919458T6 (fr)
EA (2) EA023971B1 (fr)
ES (2) ES2388310T7 (fr)
FR (1) FR14C0018I1 (fr)
HU (1) HUE049307T2 (fr)
IL (1) IL193044A (fr)
LT (1) LT2535044T (fr)
LU (1) LU92389I2 (fr)
MX (1) MX2008009647A (fr)
NL (1) NL300649I2 (fr)
PL (2) PL2535044T3 (fr)
PT (2) PT2535044T (fr)
SI (2) SI1919458T1 (fr)
WO (1) WO2007089670A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707277B1 (pt) 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
JP5583022B2 (ja) 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
WO2011011733A2 (fr) 2009-07-24 2011-01-27 The Regents Of The University Of Michigan Thérapie de remplacement de facteur
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
CA2732440C (fr) * 2011-02-23 2017-10-31 Universite Laval Analogues de la cystamine pour le traitement de la maladie de parkinson
WO2013062544A1 (fr) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cystéamine dans le traitement d'une maladie fibreuse
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US20170088896A1 (en) * 2014-05-16 2017-03-30 Children's Hospital Medical Center d/b/a Cincinnati Children's Hospital, Medical Center Methods for assessing responsiveness to asthma treatment based on vnn-1 expression and promoter methylation
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
WO2017004485A1 (fr) 2015-07-02 2017-01-05 Raptor Pharmaceuticals Inc. Analogues de la cystéamine résistant à l'ado et utilisations de ceux-ci
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (fr) 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations de cystéamine et de dérivés de cystéamine
US11576871B2 (en) 2016-11-16 2023-02-14 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
WO2019060704A1 (fr) * 2017-09-22 2019-03-28 University Of Florida Research Foundation Dispositifs et procédés pour la réduction de cristaux de cystine in vivo
EP3946298A4 (fr) 2019-03-26 2023-01-25 The Regents of the University of California Composés de type amino-thyol et amino-disulfide substitués et leurs utilisations
US11656157B2 (en) * 2019-04-25 2023-05-23 Fremonta Corporation Powered sampling device
US20240009148A1 (en) * 2020-11-19 2024-01-11 Birch Therapeutics, Inc. Cystamine Formulations and Uses Thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (fr) * 1998-04-30 1999-10-30 Hemosol Inc. Complexes hemoglobine-haptoglobine
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2001058708A1 (fr) 2000-02-14 2001-08-16 Len Booysen Unite de stabilisation
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CN1596111A (zh) * 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
DK1471902T3 (da) * 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
GB2386817B (en) * 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
CN100391448C (zh) 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
ATE515261T1 (de) 2003-12-19 2011-07-15 Omega Bio Pharma Ip3 Ltd Zusammensetzungen zur behandlung von diabetes
WO2005092914A1 (fr) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Procede visant a favoriser le repliement correct de la serum-albumine humaine a l'aide d'un ligand
CA2565250C (fr) 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines pour le traitement des complications de l'hypercholesterolimie et du diabete
AU2006236150A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
KR101394245B1 (ko) 2005-12-30 2014-05-14 에스케이바이오팜 주식회사 아이속사졸 유도체 및 이의 용도
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
BRPI0707277B1 (pt) 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
JP5583022B2 (ja) * 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
WO2009100950A1 (fr) 2008-02-17 2009-08-20 Walcom Animal Science (I.P.3) Limited Matières et procédés pour améliorer la santé de crevettes

Also Published As

Publication number Publication date
US20170042845A1 (en) 2017-02-16
EA201600089A1 (ru) 2017-01-30
US20120015038A1 (en) 2012-01-19
EP2535044A1 (fr) 2012-12-19
PL1919458T6 (pl) 2017-10-31
HUE049307T2 (hu) 2020-09-28
US20120237599A1 (en) 2012-09-20
EP3659588A1 (fr) 2020-06-03
SI1919458T1 (sl) 2012-11-30
SI2535044T1 (sl) 2020-06-30
US9511039B2 (en) 2016-12-06
ES2388310T7 (es) 2017-05-03
US20150290149A1 (en) 2015-10-15
BRPI0707277A2 (pt) 2011-04-26
AU2007210005A1 (en) 2007-08-09
ES2774755T3 (es) 2020-07-22
PL2535044T3 (pl) 2020-06-29
US20160151310A1 (en) 2016-06-02
DK1919458T3 (da) 2012-08-20
EP1919458A2 (fr) 2008-05-14
EP1919458B3 (fr) 2017-01-11
MX2008009647A (es) 2008-09-25
US20150283100A1 (en) 2015-10-08
WO2007089670A2 (fr) 2007-08-09
US9198882B2 (en) 2015-12-01
US20170319523A1 (en) 2017-11-09
US11311507B2 (en) 2022-04-26
US20090076166A1 (en) 2009-03-19
DK1919458T6 (en) 2017-03-27
US9814689B2 (en) 2017-11-14
US9925158B2 (en) 2018-03-27
AU2007210005B2 (en) 2013-09-05
AU2007210005C1 (en) 2014-01-23
US9192590B2 (en) 2015-11-24
US9750708B2 (en) 2017-09-05
ES2388310T3 (es) 2012-10-11
US9925157B2 (en) 2018-03-27
US9925156B2 (en) 2018-03-27
IL193044A0 (en) 2009-02-11
US10485774B2 (en) 2019-11-26
PT1919458E (pt) 2012-08-23
EP2535044B1 (fr) 2019-12-18
US8026284B2 (en) 2011-09-27
US20190060264A1 (en) 2019-02-28
NL300649I2 (fr) 2017-01-03
US20160331691A1 (en) 2016-11-17
EA200801752A1 (ru) 2008-12-30
US20200338033A1 (en) 2020-10-29
PT2535044T (pt) 2020-03-26
CA2640531C (fr) 2017-01-03
PL1919458T3 (pl) 2012-12-31
LT2535044T (lt) 2020-04-10
EA023971B1 (ru) 2016-08-31
US20170319524A1 (en) 2017-11-09
CY1122943T1 (el) 2021-10-29
WO2007089670A3 (fr) 2007-11-29
US9795578B2 (en) 2017-10-24
CA2640531A1 (fr) 2007-08-09
US20170319522A1 (en) 2017-11-09
FR14C0018I1 (fr) 2014-04-11
BRPI0707277B1 (pt) 2021-07-13
US20150290150A1 (en) 2015-10-15
DK1919458T5 (en) 2014-03-17
EP1919458B1 (fr) 2012-07-11
US8129433B2 (en) 2012-03-06
US20160331705A1 (en) 2016-11-17
EP1919458A4 (fr) 2010-05-26
DK2535044T3 (da) 2020-03-23
IL193044A (en) 2016-04-21

Similar Documents

Publication Publication Date Title
LU92389I2 (fr) Cystéamine
DE602006004717D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007013937D1 (de) Torantagonisten
DE602007003893D1 (de) Kippambossanordnung
DE602007009267D1 (de) Reifenaufblasverfahren
DE602007009650D1 (de) Spiroindolinonderivate
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602006020192D1 (de) Riemenscheibenanorndung
DE602007009337D1 (de) Tastfeedbackvorrichtung
AT504580A3 (de) Scan-einrichtung
DE602007001280D1 (de) Getränkeextraktor
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE602006019150D1 (de) Riemenscheibenanorndung
DE602007010359D1 (de) Azaspiroderivate
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
DE602007010544D1 (de) Motorstatorstruktur
DE602007004080D1 (de) Tintenstrahlaufnehmer
DE602007007460D1 (de) Sehkrafttestsystem
DE602006016174D1 (de) Blisterverpackungsverfahren